RecruitingNCT05915013
Perampanel or placebo alongside ketamine for treatment-resistant depression
About this title
Read the official source — NCT05915013Medication studyAges 18–60United StatesPTSD
Understand this study
Who could participate?
Listed age limits: 18 years to 60 years.
- Listed locations
- New HavenSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: September 7, 2023
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 50
- Sponsor
- Yale University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT05915013
- Official title
Show the full official title
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
New Haven
Questions about this study
Who is behind this study?
The study sponsor is Yale University, a university.
Does this study involve medication?
Yes. The study involves medication, including ketamine, Perampanel and Placebo.
Who can participate?
Listed age limits: 18 years to 60 years.
Is this study still recruiting?
The registry lists this study as recruiting.
